FindTrial
Sign In

Increasing the survival of children with blood cancer in India using a standard treatment approach.

Improving Survival in Childhood Acute Lymphoblastic Leukemia in India (ISCALL): ICiCLe Implementation Study - ISCALL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/12/060828
Enrollment
4000
Registered
2023-12-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Cancer Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed pediatric acute lymphoblastic leukemia (ALL).

Exclusion criteria

Exclusion criteria: 1. Relapsed or refractory ALL. 2. Mixed-phenotype acute leukemia.

Design outcomes

Primary

MeasureTime frame
Build capacity and expertise in regional cancer hospitals for managing pediatric acute lymphoblastic leukemia thereby improving survival outcomes.Timepoint: 3 years—

Secondary

MeasureTime frame
Identify barriers and enablers of implementing the ICiCLe-1 protocol in selected public hospitals.Timepoint: 3 years—

Countries

India

Contacts

Public ContactVenkatraman Radhakrishnan

Cancer Institute

venkymd@gmail.com9498082771

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026